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Cronobacter is a class of Enterobacteriaceae that cause infections in neonates, especially
those born prematurely. Over 90% of these infections have been linked epidemiologically
to powdered infant formula (PIF). Contamination of PIF can occur at manufacture, recon-
stitution, or storage of reconstituted product. Intrinsic properties that enable Cronobacter
to cause disease include resistance to heat, ultraviolet radiation, oxygen radicals, stomach
acids, and pasteurization; an ability to utilize sialic acid (a nutrition additive to PIF that
facilitates the organism’s growth and survival), and an exceptional affinity for biofilms in
enteral feeding tubes. As part of ongoing endeavors to reduce the incidence of neonatal
PIF-associated Cronobacter infections, the World Health Organization and the US Food
and Drug Administration have established guidelines for PIF production, preparation for
infant feeding, and storage of reconstituted product.
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Introduction
Cronobacter spp. belong to the Enterobacteriaceae family and are oxidase-negative, facultative
anaerobic, Gram-negative bacilli with circumferentially arranged flagellae that render the microor-
ganisms their motility (1, 2). Before 2008, the genus Cronobacter spp. was referred to singularly as
Enterobacter sakazakii in themedical literature until it was noted that there was significant variability
among the various E. sakazakii isolates. This finding led to their reclassification to the Cronobacter
genus (3).
The natural habitats of Cronobacter spp. are predominantly plant and organic material. The
pathogen has been isolated from various food sources – cheese, meat, milk powder, powdered infant
formula (PIF), infant weaning foods, chocolate, dry cereals, potato flour, fresh and dried herbs
and spices, and pasta (3, 4). The microorganism has also been isolated from the nasopharynx and
gastrointestinal tract of humans, the home environment (e.g., house dust, vacuum cleaner collection
bags, and kitchen utensils), hospital environments, flies and rodents, and in PIF manufacturing
facilities (4). However, when compared with other members of the Enterobacteriaceae family or with
non-fermentative Gram-negative bacilli (e.g., Pseudomonas spp. or Acinetobacter spp.), Cronobac-
ter spp. have rarely been implicated as a significant cause of healthcare-associated infections or
outbreaks (5).
Epidemiology of PIF-Associated Cronobacter Infections
Cronobacter spp. are associated with systemic infection, meningitis, and necrotizing enterocolitis in
premature infants. The incidence of infection in the US is reported to be >9 infections per 100,000
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neonates of very-low-birth-weight (4, 6, 7). There are much fewer
reported cases of C. sakazakii infections in adults with most
occurring in persons with malignancies and other debilitating
conditions (8, 9).
In a comprehensive review of Cronobacter infections docu-
mented in Centers for Disease Control and Prevention (CDC),
US Food and Drug Administration (FDA), and World Health
Organization (WHO) records, peer-reviewed publications, and
personal communications from across the globe for the period
1958 through 2010, Jason confirmed the following: (a) neonates
were predominantly affected (99% of case-infants <3months of
age); (b) 90% of case-infants had received PIF beforehand; and (c)
>50% of the infections ascertained during 2004–2014 occurred in
the home setting (10).
Friedemann studied >100 neonatal Cronobacter spp. infec-
tions between 2000 and 2008 and documented a 42% mortality
among neonates with Cronobacter spp. meningitis (11). Among
C. sakazakii infant case consultations conducted by CDC during
1998–2005, 92% of infants for whom information on feeding
practices were available had received a PIF product (12).
Before 1994, C. sakazakii was not recognized as a significant
cause of neonatal infection and its association with PIF had not
yet been established. Since then, amyriad of published reports and
studies have identified contaminated PIF as the main risk factor
for neonatal Cronobacter spp. infections (10, 12–21). C. sakaza-
kii strains appear to elicit the type 2 immune response, which
is known to be inefficient in fighting intracellular infections,
and would explain neonatal susceptibility to unique Cronobacter
strains (22).
Contamination with Cronobacter spp. is a global issue. For
example, Cronobacter spp. have been isolated from PIF in Korea,
from salads, vegetables, minced meat, and produce in Thailand,
and from feed and grain samples in Australian farms (23–27).
Why PIF is at risk for Cronobacter spp.
Contamination?
Intrinsic contamination of PIF can occur at any stage during
manufacture at the factory before distribution of product for retail;
extrinsic contamination of product can occur after the factory
container is first opened by the user; at any stage of reconstitution
through the use of contaminated water, utensils, work surfaces;
at the time of feeding (e.g., using contaminated feeding bottles
or enteral tubing with existing biofilm); or because of inappro-
priate storage conditions (e.g., poor refrigeration or storage for
too long at room temperature) (7). Underlying all the occurrences
(whether at the site of manufacture, or during reconstitution at
the hospital, or the home) is unsatisfactory or non-adherence to
appropriate infection control practices and procedures.
Because reconstitution of PIF in hot water significantly reduces
Cronobacter bioburden, it is believed that the manufacturing
phase after pasteurization is the juncture where intrinsic contam-
ination frequently occurs. Contamination of PIF can occur if the
plant-derived PIF ingredients are not properly pasteurized with
prior heat treatment (28, 29). The importance of having a validated
pasteurization process for PIF manufacture is underscored by
the fact that bioburden levels in contaminated PIF product are
generally low (never> 1cfu/gram) (3, 4, 21).
Powdered infant formula contamination can occur during the
remaining stages in the production process, especially during
phases close to the packing of the final product (30, 31). Proudy
et al. found that themajority (78%) of isolates were recovered from
processing areas (surfaces around dryers and blenders); 12% from
ingredients and 10% from final product (31).
Intrinsic properties and survival mechanisms that enable
Cronobacter spp. to end up as a PIF contaminant include resis-
tance to desiccation and osmotic stresses (3). The microorganism
has a heteropolysaccharide capsule that is resistant to osmotic
desiccation.Cronobacter strains can therefore survive for relatively
long periods (often >2 years) in the desiccated state in PIF and
other powdered foods. By contrast, non-capsulated strains have
shorter survival spans and are relatively less pathogenic (3).
Cronobacter spp. are also tolerant to acids, a property that
renders them resistant to the low pH environment in the human
stomach; some species produce an enterotoxin that is heat-stable
and able to survive pasteurization of PIF (16). Themicroorganism
also generates an endotoxin lipopolysaccharide that facilitates the
translocation of the bacteria across the intestinal wall and across
the blood-brain barrier (4). This endotoxin is heat-stable and able
to remain viable for long periods in reconstituted PIF (16).
Sialic acid is an additive to PIF during manufacture because
of its reported ability to foster healthy brain development in
the neonate (4). C. sakazakii is unique within the Cronobacter
genus in that it can utilize sialic acid for growth. This property
enables C. sakazakii to remain viable in PIF brands that are both
contaminated with the microorganism and fortified with sialic
acid.
Cronobacter spp. bacterial cells tend to attach more readily
to hydrophobic surfaces, such as Teflon and plastics, than to
hydrophilic surfaces, such as glass and metals (16). Thus, if PIF
is contaminated with Cronobacter spp. during manufacture, the
reconstitution process basically allows formation of amedium that
will facilitate bacterial growth, especially if containers and feeding
bottles are made of Teflon or plastic materials.
Cronobacter spp. can form biofilms, which render them resis-
tant to high-level disinfection (1). The potential for biofilms to
play a key role in the chain of transmission is underscored by
the observation that, compared with other Enterobacteriaceae,
Cronobacter spp. tend to have the highest biofilm cell density.
Several outbreaks of Cronobacter infections abroad and in the
US have involved infants who were fed reconstituted PIF via
enteral feeding tubes over a period of several hours at ambient
temperature (2, 4, 21). Enteral feeding tubes with biofilmsmay act
as loci for the attachment and multiplication of Cronobacter spp.
Thus, organisms will enter the stomach of the neonate whatever
type of infusate or feed bolus passes through an enteral tube with
a colonized biofilm. This is the likely scenario in the neonatal
critical care setting rather than the home.
Multiplication of Cronobacter in the syringe used for introduc-
ing reconstituted PIF through the enteral feeding tubes may also
cause large numbers of the microorganism to be introduced into
the infant, especially if the filled syringe was stored at room tem-
perature after reconstitution (4). For enteral tubes with aged, col-
onized biofilms, cells shed from the biofilm may survive passage
through the neonate’s stomach and contribute to the onset of
infection (4, 32, 33).
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Environmental and Product Testing
Recommendations
Food andDrugAdministration instituted amethod that combines
a polymerase chain reaction (PCR) assay in combination with two
chromogenic agars that reduce the time needed for identifying
the microorganism from 5 to 3 days (23). FDA’s end-product
testing protocol is based on the presumption that the pathogen
is uniformly distributed througout PIF batches deemed to be
contaminated with Cronobacter. In fact, Cronobacter spp. tend to
be non-homogeneously distributed in PIF by clumping to form
spatial clusters in end-product (34). This property limits the utility
of random sampling of PIF batches for quality assurance or public
health surveillance.
The FDA method recommended for Cronobacter ascertain-
ment has since been revised to combine real-time PCR, chro-
mogenic agars, and RAPID ID 32E biochemical tests for isolation
and detection of Cronobacter within 24–48 h (35, 36). For epi-
demiologic characterization and analyses, PFGE with two restric-
tion enzymes is currently the most commonly used molecular
method (37).
Global Surveillance of Cronobacter spp.
Infections
Most serious cases of Cronobacter neonatal infections during the
past 30 years have been caused by strains with a highly stable
molecular sequence profile (C. sakazakii sequence type 4 or ST4)
(23, 38). These four distinct pulse-types have been implicated in
outbreaks associated with necrotizing enterocolitis, septicemia,
or meningitis. Phenotyping schemes and 16S rDNA sequence
analyses have identified a total of 16 biotypes among Cronobacter
spp. (39–44).
However, only one specific pulse-type appears to be associated
with significant mortality and the ability to penetrate intestinal
and blood-brain barrier cells (40, 41). At the present time,molecu-
lar typingmethods are being increasingly used as a faster andmore
reliable tool to identify, classify, study genomic diversity, and
track sources of infection, and have largely replaced phenotyping
methods in the characterization of Cronobacter spp. (2, 44).
In 2004, the WHO instituted a molecular typing scheme to
enable the international control of the Cronobacter spp. infec-
tions. Baldwin and colleagues surmised that sequencing data
from multiple gene loci rather than one locus might be better
phylogenetic markers and would enable better discrimination
between strains compared with 16S rDNA sequencing (39). They
established a comprehensive genotyping scheme based on multi-
locus sequence typing (MLST) forCronobacter spp. The scheme is
based on seven gene loci with specific functions, including DNA
repair, replication, amino acid biosynthesis, and wide distribution
across the chromosome. This led to the establishment of the
Cronobacter PubMLST genome and sequence definition database
(http://pubmlst.org/Cronobacter/) containing over 1000 isolates
and detailed data on specific clonal lineages linked to neonatal
meningitis and adult infections (44, 45). This database is a central,
open access, reliable, sequence-based source for researchers. It
enables integration of clinical, epidemiologic, microbiologic, and
molecular typing data and retrospective analyses of historic cases
and outbreaks. By applying theMLST scheme to over 1000 strains,
Forsythe and colleagues identified 298 definable sequence types.
Of these 298 strains, only one – C. sakazakii clonal sequence type
4 – again was found to be associated with neonatal meningitis
(45). This strain is thought to be a stable clone because it has been
identified in seven countries for over 50 years (46).
Prevention of PIF-Associated Cronobacter
Infections in Neonates
Though there are no specific testing recommendations, the
Food and Agriculture Organization/World Health Organization
(FAO/WHO) established a list of recommendations for hospitals
and homes regarding PIF preparation for infants during the first
2months of life, when the risk of infection is highest (47, 48).
These recommendations are summarized as follows:
(i) PIF should be reconstituted with hot water (>70°C) to
reduce the Cronobacter spp. vegetative concentration.
(ii) Utensils for formula preparation must be disinfected.
(iii) Reconstituted PIF should be refrigerated at 4°C if not used
immediately, with disposal if not used within 24 h of prepa-
ration.
(iv) Reconstituted PIF should be kept at room temperature for a
maximum of 4 h if not used immediately, and should never
be kept warm in bottle heaters or thermos flasks.
(v) If storage is deemed necessary or unavoidable, it should be
at temperatures<5°C.
(vi) Hospitals need to establish protocols, in the event of product
recall, so that product batch follow-up and accurate data
aggregation could be carried out.
Maintenance of enteral feeding tubes in neonates is of
paramount importance in the efforts to prevent healthcare-
associated adverse events, especially in neonatal intensive care
units. Neonatal critical care specialists, infection control preven-
tionists, and hospital epidemiologists need to appreciate the risks
associated with biofilm formation in enteral feeding tubes used
for neonatal nutrition. Healthcare administrators need to ensure
that PIF procured for feeding high-risk infants in their respec-
tive facilities is sterile or has undergone a validated sterilization
process (23).
Regulatory standards for infant food manufacturers need to
be improved. Yan et al. recommend effective environmental
monitoring programs, good manufacturing practice guidelines,
and procedures and hazard analysis and critical control point
(HACCP) systems to control the risk of microbiological con-
tamination along the entire production chain, from the start-
ing raw materials, throughout the entire process, until the final
product is ready for distribution (23). PIF manufacturers also
need to improve the labeling of PIF products and communication
with consumers to enhance awareness of the correct methods
for reconstituting PIF products. Education of healthcare profes-
sionals to help them provide quality training for parents and
caregivers in PIF preparation, handling, and storage is particularly
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important for economically less-developed countries, where PIF
use is relatively common.
In conclusion, adherence to regulatory standards by PIF pro-
ducers and to FAO/WHO guidelines for PIF reconstitution and
storage by consumers, and continuing surveillance and educa-
tional activities by CDC, FDA, and WHO are essential for the
prevention of PIF-associated Cronobacter infections and other
opportunistic pathogens in neonates.
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